Revance Therapeutics | RVNC - Les Charges D'Exploitation



Les Charges D'Exploitation Changement Date
AbbVie USD 10.81B 13.45B 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Cara Therapeutics USD 5.94M 983K 2025-09
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
J&J USD 18.97B 2.38B 2025-12
Merck USD 10.16B 558M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
P&G USD 16.55B 16M 2025-12
Pacira USD 193.68M 27.32M 2025-12
Supernus Pharmaceuticals USD 197.75M 54.54M 2025-12